Allan Bream

Nov 22, 2024 | bioprocessintl.com | Xiaojun Liu |Brian Gazaille |Allan Bream |Tereza Pavlištová

Gene therapies are emerging as promising treatments for previously untreatable genetic disorders, with adeno-associated viruses (AAVs) being the preferred vector for gene delivery. However, AAV-based gene therapies face challenges in production, including cost, complexity, and scalability. With the gene therapy market projected to grow significantly, drug developers are seeking platforms that streamline AAV production.

Oct 17, 2024 | bioprocessintl.com | Brian Gazaille |Allan Bream |Brita Hobmann

Guided by standardized production and purification platforms, developers of monoclonal antibodies (mAbs) and other recombinant-protein therapeutics can take a relatively straightforward path when designing and establishing facilities for commercial-scale operations. By contrast, designing gene-therapy (GT) facilities involves a more complex calculus. Multiple approaches are available for producing transgene-bearing viral vectors at commercial scales.